Skip to content
The Nexus
DossierENTITY

PURPOSE 2

Coverage of PURPOSE 2 in the Nexus archive.

Earliest in view: Aug 1 · 18:38 UTCMost recent: Aug 1 · 18:38 UTC
Co-mentioned in this coverage
lenacapavirtopic1Yeztugotopic1PURPOSE 1topic1HIVtopic1PrEPtopic1MedPage Todayorganization1
Recent coverage
  • HEALTHAug 1 · 18:38 UTCMEDPAGE TODAY
    Long-Acting Lenacapavir Still Delivered Effective HIV PrEP After a Year

    A year-long extension of the PURPOSE 1 and PURPOSE 2 trials found that twice-yearly injectable lenacapavir (Yeztugo) for HIV PrEP resulted in only one new HIV infection. The drug demonstrated high effectiveness in preventing HIV over the study period.

PURPOSE 2 · Dossier · The Nexus